{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Denmark financial news", "home_page_url": "https://sharemaestro.com/newsreel/dk/", "feed_url": "https://sharemaestro.com/newsreel/dk/feed.json", "description": "Latest financial and company news from Denmark, newest first, with sector and industry sections and links to every source article.", "language": "en", "items": [{"id": "source:ec2a4ba62697c7e31424bdbff7c52ac155f8e38c37ca07c1b256712c1aad43cd", "url": "https://finance.yahoo.com/m/4c7d3df5-ab39-3708-a05b-9470198e52c5/vestas-secures-order-with.html", "external_url": "https://finance.yahoo.com/m/4c7d3df5-ab39-3708-a05b-9470198e52c5/vestas-secures-order-with.html", "title": "Vestas secures order with Statkraft Peru for new wind project", "content_text": "Statkraft Peru has selected Vestas for the development of the 72 MW Emma wind farm in Peru, located in the Piura region. Continue Reading", "date_published": "2026-08-14T11:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "VWS"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VWS", "name": "Vestas Wind Systems A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fdf23c07-cb98-4457-af41-1b0a77013cc9/"}]}}, {"id": "source:e142f91199ddc701efe333aa5e8027026f2517e3c090202450a3265d89e820a2", "url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bekaert-share-buyback-program-liquidity-061500238.html", "title": "Bekaert: Update on the Share Buyback Program and the Liquidity Agreement", "content_text": "Bekaert Update on the Share Buyback Program and the Liquidity Agreement Period from 6 August 2026 to 12 August 2026 Share Buyback Program On 26 February 2026, Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to \u20ac 75 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 6 August 2026 to 12 August 2026, Kepler Cheuvreux SA on behalf of Bekaert has bought 56 000 shares. The table below provides an overview of the transactions under th", "date_published": "2026-08-14T06:15:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "SCHO"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SCHO", "name": "Aktieselskabet Schouw & Co.", "sentiment_url": "https://sharemaestro.com/sentiment/e767da2c-55a0-4f5a-871d-d98ce9e43e45/"}]}}, {"id": "source:628df1dfc51b43eaf5176f665aa8074ea9d077a0712fc5bd8d80d1a4d67c31c5", "url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/afarak-group-interim-report-h1-060000892.html", "title": "AFARAK GROUP: INTERIM REPORT H1 2026", "content_text": "Afarak Group SE 07:00 London, 09:00 Helsinki, 14 August 2026 - Afarak Group SE (\"Afarak\" or \"the Company\") (LSE: AFRK, NASDAQ: AFAGR) FINANCIAL INTERIM RELEASE H1 2026 H1/26 H1/25 2025 Revenue EUR million 57.1 77.1 141.3 EBITDA EUR million 1.6 6.9 -0.2 EBIT EUR million 0.5 5.9 -2.6 Earnings before taxes EUR million 0.1 3.4 -7.5 (Loss) / Profit for the period EUR million -0.7 2.4 -8.9 Earnings per share EUR 0.00 0.01 -0.03 EBITDA margin 2.8% 9.0% -0.2 EBIT margin 0.8% 7.7% -1.8 Earnings margin 0.2% 4.5% -5.3 Personnel (end of period) 625 613 626 FIRST HALF 2026 HIGHLIGHTS The Group recorded an ", "date_published": "2026-08-14T06:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SCHO"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SCHO", "name": "Aktieselskabet Schouw & Co.", "sentiment_url": "https://sharemaestro.com/sentiment/e767da2c-55a0-4f5a-871d-d98ce9e43e45/"}]}}, {"id": "source:0ada6890cb22d71f9eeaebf5baac970b5dab8f70dae2057cf86afa45eae8cb52", "url": "https://finance.yahoo.com/markets/stocks/articles/rottneros-ab-lts-0h0l-q2-010326334.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/rottneros-ab-lts-0h0l-q2-010326334.html", "title": "Rottneros AB (LTS:0H0L) (Q2 2026) Earnings Call Highlights: EBITDA Swings to Positive as Cost ...", "content_text": "This article first appeared on GuruFocus. EBITDA: SEK 31 million in Q2 2026, up from SEK -15 million in Q2 2025. Net Turnover (Rolling 12 Months): Approximately SEK 2.3 billion. Production Volume (Rolling 12 Months): 328,000 tons. NBSK Price: Down 9% in U.S. dollars year-over-year in Q2; dollar weakened by 3% in the same period. Wood Cost: Major cost improvement driver; accounted for 45% of cost structure in the first half of 2026. Fixed Costs: Reduced via savings program; personnel down to 266 from 288 a year ago. Investments: Expected to be approximately SEK 60 million this year versus SEK 1", "date_published": "2026-08-14T01:03:26+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "KBHL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "KBHL", "name": "K\u00f8benhavns Lufthavne A/S", "sentiment_url": "https://sharemaestro.com/sentiment/39ccf012-eeda-42f8-b9b1-a9e592c5a0a4/"}]}}, {"id": "source:15124cfddcb43f6b519dcb86a0f9879392598673fec5c742e5bf9f1cf72c0ba4", "url": "https://finance.yahoo.com/m/d472cc80-6434-3d54-a945-56936be169f6/the-shipping-crunch-is.html", "external_url": "https://finance.yahoo.com/m/d472cc80-6434-3d54-a945-56936be169f6/the-shipping-crunch-is.html", "title": "The Shipping Crunch Is Getting Worse. What It Means for Walmart, Tesla, and More.", "content_text": "Walmart and more stocks will feel the effects of the capacity constraints, delays, and higher prices reported by shipping giants Maersk and Hapag-Lloyd. Continue Reading", "date_published": "2026-08-13T19:47:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:010b90069f5aab09fcd55ea3308546615edb4acf663a8aa864a28e0a88e4b4a0", "url": "https://finance.yahoo.com/economy/articles/top-west-coast-port-sees-182739709.html", "external_url": "https://finance.yahoo.com/economy/articles/top-west-coast-port-sees-182739709.html", "title": "Top West Coast port sees second-best July on record", "content_text": "The Port of Long Beach ran to its second-busiest July on record and the fourth-strongest month in its 115-year history. Long Beach, which with adjoining Port of Los Angeles comprises the top San Pedro Bay import gateway, moved 928,508 twenty foot equivalent units (TEUs) in July, down from 1.7% from July 2025. Imports were essentially flat, off 0.1% to 467,461 TEUs, while exports increased 14.8% to 104,843 TEUs. Empty containers, frequently an indicator of future imports, fell 7.4% to 356,205 TEUs.SONAR Ocean Booking Index for China-Long Beach containers is elevated from a year ago. Analysts sa", "date_published": "2026-08-13T18:27:39+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:fbc34f638d60614853aad5312c3998c87653547e35ed5b1106342b36860223aa", "url": "https://finance.yahoo.com/m/d472cc80-6434-3d54-a945-56936be169f6/walmart%2C-tesla%2C-fedex%2C-and.html", "external_url": "https://finance.yahoo.com/m/d472cc80-6434-3d54-a945-56936be169f6/walmart%2C-tesla%2C-fedex%2C-and.html", "title": "Walmart, Tesla, FedEx, and More Winners and Losers From Shipping\u2019s Rough Seas", "content_text": "Walmart, Tesla, and more stocks will feel the effects of the capacity constraints, delays, and higher prices reported by shipping giants Maersk and Hapag-Lloyd. Continue Reading", "date_published": "2026-08-13T17:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:0bca75b8bbc2a8fa3539987191796c6707dd6e26260af2ed0b559caa56026031", "url": "https://finance.yahoo.com/healthcare/articles/invitation-presentation-alk-first-six-140600422.html", "external_url": "https://finance.yahoo.com/healthcare/articles/invitation-presentation-alk-first-six-140600422.html", "title": "Invitation to the presentation of ALK\u2019s first six months (Q2) 2026 results on Thursday, 20 August 2026", "content_text": "ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK's management will comment on the results for the first six months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen S\u00f8lje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted live and be available for replay on ALK's", "date_published": "2026-08-13T14:06:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALK-B", "name": "ALK-Abell\u00f3 A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e5a5798a-6e6b-48ed-9dec-153219564368/"}]}}, {"id": "source:6c834a7565c41aed8cf59f1f44b63165ff9a14a1f7485e1d4f874817e28f9520", "url": "https://finance.yahoo.com/energy/articles/rsted-q2-2026-net-profit-131354781.html", "external_url": "https://finance.yahoo.com/energy/articles/rsted-q2-2026-net-profit-131354781.html", "title": "\u00d8rsted Q2 2026 net profit drops 79% to $106m", "content_text": "Danish renewables company \u00d8rsted reported a net profit of DKr687m ($106m) for the second quarter of 2026 (Q2 2026), down by 79% from DKr3.4bn ($524.5m) in the same period of 2025. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) for the quarter fell 18% year-on-year to DKr5.4bn, compared with DKr6.6bn a year earlier. EBITDA excluding new partnerships and cancellation fees grew by 2% to DKr5.4bn, up from DKr5.3bn in the prior-year quarter. In the second quarter, the offshore business generated EBITDA of DKr4.4bn, marking an increase from DKr4bn in the prior-year period, ", "date_published": "2026-08-13T13:13:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ORSTED"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ORSTED", "name": "\u00d8rsted A/S", "sentiment_url": "https://sharemaestro.com/sentiment/6d1dab47-40f5-4c50-9af7-8c5a8cd51206/"}]}}, {"id": "source:ccd1a87c032d9a8215ff33a6960d6d139882f76a3ff4a66f7f90e825110b2ab4", "url": "https://finance.yahoo.com/markets/stocks/articles/maersk-raises-2026-outlook-again-130249972.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/maersk-raises-2026-outlook-again-130249972.html", "title": "Maersk raises 2026 outlook again as earnings surge", "content_text": "A.P. Moller-Maersk raised its full-year earnings outlook after second-quarter revenue climbed 20% year over year and EBITDA reached $3.0 billion, as robust Far East export demand, higher spot rates and congestion across key trade lanes lifted results. Revenue rose to $15.8 billion in the second quarter from $13.1 billion a year earlier. EBIT increased to $1.6 billion from $845 million, producing a 10% EBIT margin. Ocean was the principal earnings driver, adding $2 billion in revenue during the quarter. The Copenhagen-based company (OTC: AMKBY) said disruption to traffic through the Strait of H", "date_published": "2026-08-13T13:02:49+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:a189ce4bdb9e9d0387df06ba6a64223846a291e827b2c4d97e5b888d3b0f94f8", "url": "https://finance.yahoo.com/markets/stocks/articles/gujarat-pipavav-port-ltd-bom-130052901.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/gujarat-pipavav-port-ltd-bom-130052901.html", "title": "Gujarat Pipavav Port Ltd (BOM:533248) (Q1 2027) Earnings Call Highlights: Strong Profit Growth ...", "content_text": "This article first appeared on GuruFocus. Release Date: August 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Strong financial performance with revenue up 33% YoY, EBITDA up 45%, and net profit up 46% in Q1 FY2027. Underlying EBITDA margin expanded by 200 basis points to 61%, excluding one-off duty benefit scripts. RoRo volumes surged 53% YoY, with full-year guidance of 260,000-270,000 cars. New container service (FI2) with Maersk started in June, expected to offset some volume loss from the suspended Shaheen servic", "date_published": "2026-08-13T13:00:52+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:d98dc1f3997f18efbb7b1754b4116fc7d8c07ceac98b4d9b660f6ef716d7014b", "url": "https://finance.yahoo.com/markets/stocks/articles/initiates-second-phase-share-buy-123500514.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/initiates-second-phase-share-buy-123500514.html", "title": "Initiates second phase of share buy-back program", "content_text": "A.P. M\u00f8ller - M\u00e6rsk A/S ANNOUNCEMENT A.P. M\u00f8ller - M\u00e6rsk A/S \u2013 Initiates second phase of share buy-back program As announced on 5 February 2026, A.P. M\u00f8ller - M\u00e6rsk A/S (the \"Company\") has decided to launch a share buy-back program of up to DKK 6.3 billion (around USD 1 billion) to be executed over a period of 12 months. The first phase, which started on 9 February 2026, was completed on 5 August 2026. The total market value of the shares acquired in the first phase amounted to DKK 3.15 billion. The second phase of the share buy-back program will run from 13 August 2026 up to and including 29 ", "date_published": "2026-08-13T12:35:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:12b3a1345c9d74820e37a14682302605931dca8eb284231aa63a86b6ce40e8e9", "url": "https://finance.yahoo.com/markets/stocks/articles/ringkj-bing-landbobank-cpse-rilba-121214540.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/ringkj-bing-landbobank-cpse-rilba-121214540.html", "title": "Ringkj\u00f8bing Landbobank (CPSE:RILBA) Lifts Guidance With Valuation Still Open To Debate", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Ringkj\u00f8bing Landbobank (CPSE:RILBA) has moved back into focus after reporting half year 2026 results and raising its full year profit guidance, a combination that gives investors fresh earnings data to assess. See our latest analysis for Ringkj\u00f8bing Landbobank. Ringkj\u00f8bing Landbobank's latest guidance increase comes after a solid run in the stock, with the share price gaining 13.8% over the past 90 days and a 1 year total shareholder return of 17.9%, suggesting momentum has been building", "date_published": "2026-08-13T12:12:14+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RILBA"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RILBA", "name": "Ringkj\u00f8bing Landbobank A/S", "sentiment_url": "https://sharemaestro.com/sentiment/de7e150f-de2c-462e-9b0b-2cb33d527912/"}]}}, {"id": "source:6a9ef7de3c3c4e0f617168c7947a2a19328d0a9ca572f6c5356f91e1ea48ad7b", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-zldpf-surpasses-q2-113502082.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-zldpf-surpasses-q2-113502082.html", "title": "Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates", "content_text": "Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +2,150.00%. A quarter ago, it was expected that this company would post a loss of $1.57 per share when it actually produced a loss of $0.87, delivering a surprise of +44.59%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Zealand Pharma AS, w", "date_published": "2026-08-13T11:35:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:1eb3095fe93db01645050a1f2e1ca1911617c4100f31d438c0109b8dc54343fc", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-cpse-zeal-stock-081006793.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-cpse-zeal-stock-081006793.html", "title": "Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares may now be closer to fairly priced than a clear bargain. Over five years, Zealand Pharma has returned 90.3%, which puts current buyers in a different position to those who entered earlier in the story. The recent $100 million royalty deal with Royalty Pharma can support funding for rusfertide and other priorities. Reliance on s", "date_published": "2026-08-13T08:10:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:af9d6cbd696cb3066975984c9c0783a45263d27ce94609679a57430c530ebb9e", "url": "https://finance.yahoo.com/economy/articles/maersk-lifts-full-profit-guidance-075941510.html", "external_url": "https://finance.yahoo.com/economy/articles/maersk-lifts-full-profit-guidance-075941510.html", "title": "Maersk lifts full-year profit guidance to $6.5bn", "content_text": "The chief executive of Maersk called for a big increase in investment in trade infrastructure such as ports, trucks and rail as the world's second-largest container shipping group raised its full-year profit guidance again. Vincent Clerc, chief executive of the Danish company that Silver Upgrade to read this Financial Times article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-13T07:59:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:6c1b96772c95fab935750af34a9e1eeb0fd251d847cf3a0432e183399083258b", "url": "https://finance.yahoo.com/markets/stocks/articles/interim-report-q2-2026-055300549.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/interim-report-q2-2026-055300549.html", "title": "Interim Report Q2 2026", "content_text": "A.P. M\u00f8ller - M\u00e6rsk A/S The Interim Report for the 2nd Quarter 2026 for A.P. M\u00f8ller - M\u00e6rsk A/S is hereby enclosed. CEO of A.P. M\u00f8ller - M\u00e6rsk A/S, Vincent Clerc, states: The second quarter was yet another proof point of the new era of heightened volatility we have entered. Strong, broad-based demand from the Far East since 2024 has resulted in significantly more unbalanced trade flows, with volume levels that are challenging landside infrastructure capacity. From ports to inland transportation, we are seeing increased congestion and disruption across multiple geographies. Our global team's ab", "date_published": "2026-08-13T05:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MAERSK-B", "MAERSK-A"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}, {"symbol": "MAERSK-A", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/bd95cad0-208a-4e08-b2c6-4c215c0b0314/"}]}}, {"id": "source:349e2109d8bc3d99722c5255003a7262edc5ce307cc446a550df0a679adaf8db", "url": "https://finance.yahoo.com/markets/stocks/articles/upgrade-guidance-full-2026-055100228.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/upgrade-guidance-full-2026-055100228.html", "title": "Upgrade of guidance for full year 2026", "content_text": "A.P. M\u00f8ller - M\u00e6rsk A/S ANNOUNCEMENT A.P. M\u00f8ller - M\u00e6rsk A/S \u2013 Upgrade of guidance for full year 2026 Guidance for full year 2026 Based on the actual performance in the second quarter of 2026, and improved visibility for the remainder of the year, A.P. M\u00f8ller - M\u00e6rsk A/S (APMM) raises its outlook for the year and now expects: Underlying EBITDA of USD 10.5-12.5bn (previously USD 8-10bn) Underlying EBIT of USD 4.5-6.5bn (previously USD 2-4bn) Free cash flow of greater than USD 0 (previously at least USD -1.5bn) This is based on a volume growth outlook for the global container market of about 4% ", "date_published": "2026-08-13T05:51:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "MAERSK-B", "MAERSK-A"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}, {"symbol": "MAERSK-A", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/bd95cad0-208a-4e08-b2c6-4c215c0b0314/"}]}}, {"id": "source:b7b0db934fc94e196b1514dddd86583b077bd91f1719c8be99b1694667cb2b19", "url": "https://finance.yahoo.com/markets/stocks/articles/netcompany-upgrade-revenue-guidance-full-052600396.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/netcompany-upgrade-revenue-guidance-full-052600396.html", "title": "Netcompany upgrade revenue guidance for full year 2026", "content_text": "Netcompany Group A/S Company announcement No. 49/2026 13 August 2026 Netcompany upgrade revenue guidance for full year 2026 Netcompany Group A/S (\"Netcompany\") raise full year revenue guidance for 2026, based on revenue growth of 40.9%, of which 15.1 percentage points were organic, for the first six months of 2026 and taking into account the current backlog and weighted pipeline. For the full year 2026, Netcompany now expects: Group revenue growth of between 16% and 20.5% (previously between 15% and 20%) Group excluding Netcompany Banking Services revenue growth of between 6.5% and 10.5% (prev", "date_published": "2026-08-13T05:26:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "NETC"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NETC", "name": "Netcompany Group A/S", "sentiment_url": "https://sharemaestro.com/sentiment/04e750fb-540b-4319-bf50-0cee98cf238c/"}]}}, {"id": "source:4c47be21db0b869f236a4343c9b21e0fe0351201a70508d8b2df37feae0ef95f", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-announces-financial-results-050000185.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-announces-financial-results-050000185.html", "title": "Zealand Pharma Announces Financial Results for the First Half of 2026", "content_text": "Zealand Pharma Company announcement \u2013 No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy. Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results, demonstrating double-digit weight loss with a tolerability profile largely comparable to placebo, supporting its potential to redefine the weight management experience for people living wit", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:407c88c9895cb5a47706d199996de4619c1a8a2b4686b24643c74d20a70f59bf", "url": "https://finance.yahoo.com/markets/stocks/articles/p-m-ller-m-rsk-011228227.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/p-m-ller-m-rsk-011228227.html", "title": "A.P. M\u00f8ller M\u00e6rsk (CPSE:MAERSK B) Refocuses On Core Logistics, Is The Valuation Still Too Rich?", "content_text": "Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. A.P. M\u00f8ller-M\u00e6rsk (CPSE:MAERSK B) is returning another shipping service to the Suez Canal and selling its Maersk Training unit to private equity firm OpenGate Capital. These moves sharpen attention on the core container and logistics business. See our latest analysis for A.P. M\u00f8ller - M\u00e6rsk. Against this backdrop, A.P. M\u00f8ller - M\u00e6rsk's 1 day share price return of 2.65% and 18.48% year to date share price return suggest momentum has been building. The 5 year total shareholder ", "date_published": "2026-08-13T01:12:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "MAERSK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}]}}, {"id": "source:a1a0ed9f4418b7f9a229661b8e7f83589e036c94201b2c2d26fac1714bf7a625", "url": "https://finance.yahoo.com/markets/stocks/articles/raute-oyj-ohel-raute-q2-011145560.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/raute-oyj-ohel-raute-q2-011145560.html", "title": "Raute Oyj (OHEL:RAUTE) (Q2 2026) Earnings Call Highlights: Strong Margins Amidst Weak Demand", "content_text": "This article first appeared on GuruFocus. Net Sales: EUR 33 million in Q2 2026, similar to Q1 2026 and lower than the year-ago period; first half net sales totaled EUR 66 million. Comparable EBITDA: EUR 4.0 million in Q2 2026, representing a 12% margin on net sales. Order Intake: EUR 18 million in Q2 2026, higher than a year ago but still at a low level; first half order intake was EUR 35 million. Earnings Per Share (EPS): EUR 0.36 in Q2 2026, down from the record-high level in the comparable period a year ago. Operating Cash Flow: Negative EUR 8 million in Q2 2026, the second consecutive quar", "date_published": "2026-08-13T01:11:45+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "KBHL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "KBHL", "name": "K\u00f8benhavns Lufthavne A/S", "sentiment_url": "https://sharemaestro.com/sentiment/39ccf012-eeda-42f8-b9b1-a9e592c5a0a4/"}]}}, {"id": "source:925017f4be8893e31a12586289c34f0c7ee514ff04b91b00d8b70dac2f840033", "url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "external_url": "https://finance.yahoo.com/energy/articles/cez-xpra-cez-q2-2026-011013959.html", "title": "CEZ AS (XPRA:CEZ) (Q2 2026) Earnings Call Highlights: Net Income Rises 10% as Windfall Tax ...", "content_text": "This article first appeared on GuruFocus. Revenue: Operating revenue decreased 5% year-on-year, primarily due to lower power prices. EBITDA: Down 20% to CZK59 billion, impacted by lower generation prices and reduced trading profits. Net Income: Increased 10% to CZK18.1 billion, driven by the absence of the windfall profit tax, which ended on December 31, 2025. Operating Cash Flow: Increased by CZK26 billion, or 55% year-on-year. Capital Expenditures (CapEx): Increased 30% year-on-year. Net Debt: Approximately 9% higher, approaching CZK200 billion. Generation and Mining EBITDA: Decreased by CZK", "date_published": "2026-08-13T01:10:13+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SCHO"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SCHO", "name": "Aktieselskabet Schouw & Co.", "sentiment_url": "https://sharemaestro.com/sentiment/e767da2c-55a0-4f5a-871d-d98ce9e43e45/"}]}}, {"id": "source:5f3ffd7b43db74effa140b90ac2ade224c7ea21f9322104f94b219d7d32d8cf0", "url": "https://finance.yahoo.com/markets/stocks/articles/iss-wbo-iss-h1-2026-010816868.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/iss-wbo-iss-h1-2026-010816868.html", "title": "ISS AS (WBO:ISS) (H1 2026) Earnings Call Highlights: Strong Organic Growth and Strategic Wins ...", "content_text": "This article first appeared on GuruFocus. Revenue: Increased by DKK3 billion compared with the first half of 2025. Organic Growth: 8.9% in the second quarter, with a like-for-like contribution of 2% for the third consecutive quarter. Operating Margin: 4.6% for the first half of 2026. Free Cash Flow: DKK600 million for the first half of 2026, including a DKK600 million one-time payment from Deutsche Telekom. Earnings Per Share: Improved by 29% compared with the first half of 2025. Retention Rate: Improved to 95%. Contract Maturity Profile: Remained at 1% for 2026. Regional Organic Growth (Q2): ", "date_published": "2026-08-13T01:08:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "ISS"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ISS", "name": "ISS A/S", "sentiment_url": "https://sharemaestro.com/sentiment/2b2aa187-9a76-4d80-9f42-ddf2f2d4d014/"}]}}, {"id": "source:75002d510a976d8fb1fd26d66ac0ca94ee02132e471459632ecb609c35c42bda", "url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "external_url": "https://finance.yahoo.com/technology/ai/articles/gft-technologies-se-wbo-gft-010536877.html", "title": "GFT Technologies SE (WBO:GFT) (H1 2026) Earnings Call Highlights: AI-Driven Growth and ...", "content_text": "This article first appeared on GuruFocus. Revenue: EUR462.6 million in H1 2026, a 5% increase in both euros and constant currencies. Adjusted EBIT: EUR33 million, up 8% year-over-year, with a margin of 7.1% compared to 6.8% in H1 2025. EBT: EUR24 million, up 26% year-over-year, with the EBT margin improving from 4.3% to 5.2%. Q2 Revenue: EUR233.04 million, a 6% increase versus Q2 2025. Q2 Adjusted EBIT: EUR16.5 million, a 10% increase versus Q2 2025. Order Backlog: Up 18% versus last year. Wynxx Soft Engineering Revenue: EUR24.4 million in actual influenced revenue in H1 2026. Wynxx Business P", "date_published": "2026-08-13T01:05:36+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SCHO"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SCHO", "name": "Aktieselskabet Schouw & Co.", "sentiment_url": "https://sharemaestro.com/sentiment/e767da2c-55a0-4f5a-871d-d98ce9e43e45/"}]}}, {"id": "source:00065397cad77d25ae4cd46e71184695e7fc762987d47000af0a47dbe12b1e59", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-cpse-zeal-royalty-231634640.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-cpse-zeal-royalty-231634640.html", "title": "Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase and sale deal with Royalty Pharma linked to rusfertide, a potential treatment for polycythemia vera. The agreement transfers Zealand Pharma's economic interests related to rusfertide, including potential future royalty rights. It also provides new funding that management plans to redeploy toward the company's key prior", "date_published": "2026-08-12T23:16:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:c207ea21f3bdcd74c15f6e961a5bd1e6f613db7c44a3abb1304c13ee62bab22b", "url": "https://finance.yahoo.com/healthcare/articles/demant-willf-q2-2026-earnings-230522384.html", "external_url": "https://finance.yahoo.com/healthcare/articles/demant-willf-q2-2026-earnings-230522384.html", "title": "Demant AS (WILLF) (Q2 2026) Earnings Call Highlights: Strong H1 Growth Fueled by Oticon Zeal ...", "content_text": "This article first appeared on GuruFocus. Revenue Growth: Group reported growth of 15% in H1 2026, with 7% organic growth and 10% acquisitive growth, primarily from KIND. Gross Margin: Increased by 1.1 percentage points, driven by strong ASP in hearing aids and the acquisition of KIND. EBIT before Special Items: DKK2.134 billion, corresponding to a margin of 16.5%, with 19% growth in local currencies. Cash Flow from Operations: DKK1.6 billion, a 6% increase compared to H1 2025. Hearing Aids Growth: 10% growth in Q2, driven by the full rollout of Oticon Zeal, with double-digit growth in North A", "date_published": "2026-08-12T23:05:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DEMANT"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DEMANT", "name": "Demant A/S", "sentiment_url": "https://sharemaestro.com/sentiment/459136d6-bfc4-4b76-8768-6b870260d4ca/"}]}}, {"id": "source:a6325fa22040e5dc4401ff094910036d501da606af5903010ffd9c8a18c147eb", "url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-zealand-pharma-enter-201000247.html", "external_url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-zealand-pharma-enter-201000247.html", "title": "Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million", "content_text": "Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder. \"We are delighted to expand our relationship with Zealand Pharma through a second collaboration, supporting the company as it continues to advance its innovative pipeline of medicines for obesity and metabolic health,\" said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. \"This transaction underscores Royalty Pharma's role as a long-term, trusted partner to biopharma companies as they advance important medicines. Furthermore, we believe rusfertide has the potential to become a transformative treatment option for patients with polycythemia vera, and we look forward to its continued progress through regulatory review.\" \"We are very pleased to work with Royalty Pharma, a leading funder of life science innovation, on this strategic financial transaction,\" said Henriette Wennicke, Chief Financial Officer at Zealand Pharma. \"This agreement converts a future potential royalty stream into immediate capital that will be redeployed against future growth opportunities in line with our key strategic priorities under our Metabolic Frontier 2030 strategy.\" Rusfertide is a potential first-in-class therapy that mimics the action of hepcidin, a natural hormone that regulates iron homeostasis and red blood cell production. By targeting the underlying mechanism of iron dysregulation in polycythemia vera, rusfertide aims to reduce excess red blood cell production and help patients achieve sustained hematocrit control. Rusfertide is administered once weekly via subcutaneous self-injection and has been generally well-tolerated in clinical trials to date. The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for rusfertide for the treatment of adults with polycythemia vera in the third quarter of 2026i and Takeda will be responsible for global commercialization. Transaction terms Under the terms of the royalty purchase and sale agreement, Royalty Pharma will provide $100 million to Zealand Pharma in exchange for its economic interests related to rusfertide, including rights to a 1% royalty on potential future global net sales of rusfertide and regulatory and commercial milestones. This consists of $50 million upon closing of the transaction with the remaining $50 million due upon the first anniversary of the closing of the agreement. Zealand Pharma will retain the right to a 0.25% royalty on annual net global sales of rusfertide greater than $1.5 billion, while Royalty Pharma will retain a 0.75% royalty on sales above $1.5 billion. Story Continues Background In June 2012, Zealand Pharma and Protagonist Therapeutics, Inc., entered into a research collaboration agreement to develop disulfide-rich peptides (DRPs). Under the agreement, Zealand Pharma was responsible for preclinical and clinical drug development of DRPs discovered under the collaboration. The research collaboration was terminated in 2014 and Protagonist's payment obligations to Zealand Pharma were clarified in a settlement agreement reached in 2021. In January 2024, Protagonist and Takeda entered into a worldwide license and collaboration agreement for rusfertide. Advisors Covington, Dechert, Jones Day and Kromann acted as legal advisors to Royalty Pharma. Goodwin acted as legal advisor to Zealand Pharma. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical compani", "date_published": "2026-08-12T20:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:ad815a30e5c1a40c334a1b739029cbfe341e613cdf0512338a7f3ca45284208d", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-enters-usd-100-200500756.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-enters-usd-100-200500756.html", "title": "Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide", "content_text": "Zealand Pharma Company announcement \u2013 No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide. The agreement unlocks value from a non-core royalty entitlement for redeployment to Zealand Pharma's key strategic priorities. Copenhagen, Denmark, August 12, 2026 \u2013 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), ", "date_published": "2026-08-12T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:288cb77f65669ea4ae1df860baddc399172d441986781ac38cbf866aebf78da0", "url": "https://finance.yahoo.com/markets/stocks/articles/maersk-cpse-maersk-b-returns-181410215.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/maersk-cpse-maersk-b-returns-181410215.html", "title": "Maersk (CPSE:MAERSK B) Returns Another Service To The Suez Canal", "content_text": "Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. A.P. M\u00f8ller - M\u00e6rsk (CPSE:MAERSK B) is returning another shipping service to the Suez Canal after earlier disruptions linked to security and logistical issues. The company has agreed to sell Maersk Training, its global safety training business, to private equity firm OpenGate Capital. Both moves point to adjustments in Maersk's operational routes and a sharper focus on core container and logistics activities. For a broader view of how infrastructure rela", "date_published": "2026-08-12T18:14:10+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "MAERSK-B", "MAERSK-A"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "MAERSK-B", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/879b1e0d-d783-4781-b0f8-4c120155a333/"}, {"symbol": "MAERSK-A", "name": "A.P. M\u00f8ller - M\u00e6rsk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/bd95cad0-208a-4e08-b2c6-4c215c0b0314/"}]}}, {"id": "source:fef18f4e280685de7dbc6c50d1d93df3658df1ac06d7c1efcd63083fe71bf0e5", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "external_url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "date_published": "2026-08-12T17:29:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:e166086d8f278a4e7b82c751cc0bfc38b9022f17e1ad0df5d0893cdaff849889", "url": "https://finance.yahoo.com/energy/articles/vestas-shares-surge-wind-turbine-161341125.html", "external_url": "https://finance.yahoo.com/energy/articles/vestas-shares-surge-wind-turbine-161341125.html", "title": "Vestas Shares Surge as Wind Turbine Orders Rebound", "content_text": "Shares in Danish wind turbine maker Vestas Wind Systems surged more than 20% after the company raised its full-year profit guidance and announced a \u20ac400 million share buyback, signaling a sharp recovery for the wind industry. Vestas said turbine orders jumped to 3.35 gigawatts (GW) worth \u20ac3.4 billion in the second quarter, up from 2 GW worth \u20ac2.2 billion a year earlier. Its total turbine backlog has now reached 32.5 GW, valued at \u20ac36 billion. The company reported adjusted operating profit of \u20ac446 million for the quarter, compared with just \u20ac57 million a year earlier. Its operating margin reach", "date_published": "2026-08-12T16:13:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Capital return", "VWS"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VWS", "name": "Vestas Wind Systems A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fdf23c07-cb98-4457-af41-1b0a77013cc9/"}]}}, {"id": "source:89ccdae8021599987b6aa5f490674f932ae2eb912f9372cd9d18a81117ea95ac", "url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "external_url": "https://finance.yahoo.com/real-estate/articles/nextensa-delivers-strong-half-results-155500459.html", "title": "Nextensa delivers strong half-year results, supported by several successful transactions", "content_text": "Nextensa NV PRESS RELEASE Regulated information Brussels, 12 August 2026, 5:55PM HIGHLIGHTS Nextensadeliversstronghalf-yearresults,supportedbyseveralsuccessful transactions Nextensa achieved strong results in the first half of 2026. The period was marked by several successful transactions, including the sale of Gewerbepark Stadlau in Vienna, the forward sale of The Rock and the sale of B&B Hotels in Cloche d'Or. The granting of the planning and environmental permits for Lake Side in Brussels and the reservation by Vicinity of a substantial residential portion of Bel Towers further underline th", "date_published": "2026-08-12T15:55:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SCHO"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SCHO", "name": "Aktieselskabet Schouw & Co.", "sentiment_url": "https://sharemaestro.com/sentiment/e767da2c-55a0-4f5a-871d-d98ce9e43e45/"}]}}, {"id": "source:79aa573167b0288dade2220fb06316aa2da398cd60b013468f8f899672bf751e", "url": "https://finance.yahoo.com/markets/stocks/articles/pandora-delivers-3-organic-growth-153000025.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/pandora-delivers-3-organic-growth-153000025.html", "title": "Pandora delivers 3% organic growth in Q2 - guidance upgraded", "content_text": "Pandora A/S Q2 2026 highlights Pandora delivered organic growth of 3% with LFL growth of 1% and network expansion & other of 2%. LFL in North America was -1%, EMEA remained broadly stable at -2%, whilst Asia-Pacific and Latin America saw continued strong growth at 10% and 18%, respectively. LFL growth in the Core was -1%, whilst Fuel with More saw an improvement to 6% LFL growth. The gross margin ended at 80.5%. One-off income from a partial refund of Pandora's US IEEPA tariff claim positively impacted the gross margin by 230bp. Excluding this, the gross margin remained solid at 78.2%, down 11", "date_published": "2026-08-12T15:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "PNDORA"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PNDORA", "name": "Pandora A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fe6056a4-6435-4e3d-8b23-2ad8237bb701/"}]}}, {"id": "source:d90e2209731c3b9a7749d90bee2a2e591fe83a02bb6808379f75ca9198499298", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "title": "European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading", "content_text": "European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T15:11:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:de9e2e54cd03494c7c82bc314fdfb47b59256672fe30d3fa8a7dae8f56e46b3e", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "content_text": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "date_published": "2026-08-12T15:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:3bd1d4ad8bb7d0f063cdf91911b1e774e17c9b40b57c311e89283e66b3dc6fec", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "content_text": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 2026 results provide particularly strong evidence of this transition. Pfizer's revenues excluding Comirnaty and Paxlovid increased 5% operationally, while its launched and acquired products grew 18% operationally. Pfizer also raised the midpoint of its 2026 revenue guidance by $500 million, with the company attributing roughly $1.5 billion of the improvement to better-than-expected performance of non-COVID products. Established Brands & New Products Drive PFE's Non-COVID Growth A key driving factor behind growth in non-COVID revenues has been the continued rise in sales of several established brands like Vyndaqel and alliance revenues from partner Bristol-Myers BMY for Eliquis. Some internally developed product launches are also contributing to its top-line growth. Key recent product launches include Abrysvo, the first RSV vaccine approved for older adults and for maternal immunization to protect infants; Zavzpret, a nasal spray CGRP antagonist for acute migraine treatment; Hympavzi, a once-weekly treatment for hemophilia A and B with inhibitors; Elrexfio, a BCMA-targeted bispecific antibody for relapsed or refractory multiple myeloma, and Litfulo for severe alopecia areata. PFE's Acquisitions Complement Internal R&D The company is also trying to rebuild its pipeline through acquisitions. Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years and could turn out to be transformative opportunities for the company. A key acquired product that has become a significant contributor to revenue growth is Padcev, added from Seagen. In the second quarter, revenues from Pfizer's acquired products like Padcev, Nurtec (added from Biohaven) and others grew 25% operationally, when excluding the impact of certain one-time items in the same quarter a year ago. Pfizer's Pipeline Provides a Second Wave of Growth Pfizer is rebuilding its pipeline in oncology and obesity, which it believes can drive growth in 2028 and beyond. In obesity, Pfizer plans an extensive phase III program for berobenatide, its monthly GLP-1 receptor agonist added from last year's Metsera acquisition, in 2026. Pfizer plans to start more than 20 obesity studies in 2026, including 10 phase III studies for berobenatide for obesity and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. However, in the obesity space, Pfizer lags behind leaders like Eli Lilly LLY and Novo Nordisk NVO. Story Continues The currently available and highly popular weight loss GLP therapies, Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are weekly injections. On the other hand, Pfizer's berobenatide starts off as a weekly injection and then switches to a monthly injection. Berobenatide is designed for monthly maintenance dosing. Pfizer is also advancing its oncology clinical pipeline across areas such as breast, thoracic, gastrointestinal and blood cancer. Several oncology candidates have entered late-stage development. Pfizer plans to start four pivotal studies for PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025. Besides obesity and oncology, Pfizer is advancing candidates in migraine, hemophilia, vaccines, inflammation and immunology. Several of these programs could create additional growth opportunities ove", "date_published": "2026-08-12T15:03:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:a02a97fa359459bb1b6e6c1a05a25200f63e258a063f9e1fbc0a88af6ac1969c", "url": "https://finance.yahoo.com/energy/articles/vestas-wind-systems-vwdry-q2-150115925.html", "external_url": "https://finance.yahoo.com/energy/articles/vestas-wind-systems-vwdry-q2-150115925.html", "title": "Vestas Wind Systems AS (VWDRY) (Q2 2026) Earnings Call Highlights: Revenue Surges 26% and ...", "content_text": "This article first appeared on GuruFocus. Revenue: EUR4.7 billion, an increase of 26% year-on-year, driven by strong growth in Power Solutions of 37%. EBIT Margin: 9.4%, a strong profitability improvement driven by both onshore and offshore. Earnings Per Share (EPS): EUR1.1 per share, growing 46% year-on-year. Order Intake: 3.3 gigawatts, an increase of 67% year-on-year, driven by commercial traction in both EMEA and the Americas. Power Solutions Revenue: Increased by 37% year-on-year, driven mainly by higher megawatt delivered in both onshore and offshore. Power Solutions EBIT Margin: 10.4% i", "date_published": "2026-08-12T15:01:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "VWS"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "VWS", "name": "Vestas Wind Systems A/S", "sentiment_url": "https://sharemaestro.com/sentiment/fdf23c07-cb98-4457-af41-1b0a77013cc9/"}]}}, {"id": "source:35b82ec4a033262c043e91d3e0e444d879104bf153a20386c5b8ef076f51335c", "url": "https://finance.yahoo.com/markets/stocks/articles/h-h-international-fra-j0h-150054692.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/h-h-international-fra-j0h-150054692.html", "title": "H+H International AS (FRA:J0H) (Q2 2026) Earnings Call Highlights: Poland Drives 6% Organic ...", "content_text": "This article first appeared on GuruFocus. Release Date: August 12, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points H+H International AS (FRA:J0H) delivered 6% organic growth in Q2 2026, with a return to a normalized EBIT margin of 6%. The Polish market showed strong performance, with a 19% year-on-year increase in building permits and a 25% EBITDA margin, driving overall group results. The company's strategic restructuring in Germany is yielding positive results, with annualized savings of DKK 40 million and improved ope", "date_published": "2026-08-12T15:00:54+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "KBHL", "HH"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "KBHL", "name": "K\u00f8benhavns Lufthavne A/S", "sentiment_url": "https://sharemaestro.com/sentiment/39ccf012-eeda-42f8-b9b1-a9e592c5a0a4/"}, {"symbol": "HH", "name": "H+H International A/S", "sentiment_url": "https://sharemaestro.com/sentiment/de7f446f-017d-4418-ba22-9cf11c0c0f22/"}]}}, {"id": "source:e36d474eb97ad2c336075d3dfe5a331dd95140d361056163840fbc0c12cb09bc", "url": "https://finance.yahoo.com/markets/stocks/articles/changes-full-guidance-biomar-113300186.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/changes-full-guidance-biomar-113300186.html", "title": "Changes to full-year guidance for BioMar", "content_text": "Aktieselskabet Schouw & Co. Today, BioMar has released an announcement with updated guidance for the full year 2026. BioMar now expects revenue in the range of DKK 17-18 billion against previously DKK 16-17 billion and EBIT in the range of DKK 1,200-1,300 million compared to previously DKK 1,100-1,200 million. BioMar constitutes a material part of the portfolio and is fully consolidated into the Schouw & Co. figures, and the information from BioMar will be incorporated into Schouw & Co.'s guidance. Schouw & Co. provides guidance to the market on revenue and EBITDA and will consider its consoli", "date_published": "2026-08-12T11:33:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "SCHO"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SCHO", "name": "Aktieselskabet Schouw & Co.", "sentiment_url": "https://sharemaestro.com/sentiment/e767da2c-55a0-4f5a-871d-d98ce9e43e45/"}]}}, {"id": "source:3af30d5147e0abf97da9be20011e6823f250b71129d265aa32a72112226f0145", "url": "https://finance.yahoo.com/markets/commodities/articles/novonesis-launches-optiva-triticum-help-111200660.html", "external_url": "https://finance.yahoo.com/markets/commodities/articles/novonesis-launches-optiva-triticum-help-111200660.html", "title": "Novonesis launches Optiva\u00ae Triticum to help pasta manufacturers navigate wheat volatility without compromising quality", "content_text": "Novonesis (Novozymes A/S) COPENHAGEN, Denmark, August 12, 2026 \u2013 Novonesis today announced the launch of Optiva\u00ae Triticum, a new biosolution that helps pasta manufacturers increase flexibility in wheat sourcing while maintaining the texture, firmness and eating experience consumers expect. As fluctuations in durum wheat availability and pricing continue to challenge the pasta industry, producers are seeking new ways to reduce raw material costs and strengthen supply resilience. Optiva\u00ae Triticum enables greater use of soft wheat flour in pasta applications while supporting consistent quality ac", "date_published": "2026-08-12T11:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "NSIS-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NSIS-B", "name": "Novozymes A/S", "sentiment_url": "https://sharemaestro.com/sentiment/11ec5f36-eff4-4b5e-be2f-2a6e445d852d/"}]}}, {"id": "source:a8dc7b75c918a6830a77cf3ca38e0112fa21b0d169ebb3695bde7a2b8baefbae", "url": "https://finance.yahoo.com/healthcare/articles/latest-global-microbial-biostimulants-market-073000815.html", "external_url": "https://finance.yahoo.com/healthcare/articles/latest-global-microbial-biostimulants-market-073000815.html", "title": "[Latest] Global Microbial Biostimulants Market Size/Share Worth USD 13.88 Billion by 2034 at a 10.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)", "content_text": "Custom Market Insights [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Microbial Biostimulants Market size & share revenue was valued at approximately USD 5.10 Billion in 2024 and is expected to reach USD 5.64 Billion in 2025 and is expected to reach around USD 13.88 Billion by 2034, at a CAGR of 10.5% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are BASF SE, Syngenta AG, Bayer AG, UPL Limited, Valagro S.p.A. (Syngenta Group), Isagro S.p.A. (Gowan G", "date_published": "2026-08-12T07:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "NSIS-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NSIS-B", "name": "Novozymes A/S", "sentiment_url": "https://sharemaestro.com/sentiment/11ec5f36-eff4-4b5e-be2f-2a6e445d852d/"}]}}, {"id": "source:823f75b91e7b6b40c1d27a42d89fc7466f8107516ad56ea484a3a2544c23bdef", "url": "https://finance.yahoo.com/markets/stocks/articles/martela-corporations-half-report-1-050000284.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/martela-corporations-half-report-1-050000284.html", "title": "Martela Corporation's Half Year Report 1 January - 30 June 2026", "content_text": "Martela Corporation Martela Corporation, Half year report, 12.8.2026, at 08:00 a.m. The revenue and operating result for January-June 2026 weakened compared to the same period of the previous year. April\u2013June 2026 Revenue was EUR 14.5 million (24.6), representing a change of -41.0% Comparable operating result EUR -1.6 million Operating result was EUR -0.5 million (0.1) Operating profit per revenue was -3.3% (0.5%) The result for the period was EUR -1.0 million (-0.4) Earnings per share amounted to EUR -0.26 (-0.09) January\u2013June 2026 Revenue was EUR 32.0 million (50.2), representing a change of", "date_published": "2026-08-12T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "KBHL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "KBHL", "name": "K\u00f8benhavns Lufthavne A/S", "sentiment_url": "https://sharemaestro.com/sentiment/39ccf012-eeda-42f8-b9b1-a9e592c5a0a4/"}]}}, {"id": "source:02bdde7ef50a86b3878373f3e862a443c365b815016d87163ed20b42978c8b6b", "url": "https://finance.yahoo.com/markets/stocks/articles/martela-lowers-2026-revenue-result-044000965.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/martela-lowers-2026-revenue-result-044000965.html", "title": "Martela lowers its 2026 revenue and result guidance", "content_text": "Martela Corporation Martela Corporation, Inside Information, 12.8.2026 at 07:40 a.m. Due to market uncertainty and weak demand, Martela lowers its full-year revenue and result guidance. The company estimates that its revenue for 2026 will amount to approximately EUR 66\u201373 million and that its comparable operating result will be negative by EUR 1\u20133 million. New guidance for 2026: Martela Group's full-year revenue for 2026 is estimated to amount to approximately EUR 66\u201373 million. The comparable operating result is estimated to be negative by EUR 1\u20133 million. Previous guidance for 2026: Martela ", "date_published": "2026-08-12T04:40:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "KBHL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "KBHL", "name": "K\u00f8benhavns Lufthavne A/S", "sentiment_url": "https://sharemaestro.com/sentiment/39ccf012-eeda-42f8-b9b1-a9e592c5a0a4/"}]}}, {"id": "source:71a851c14fd85444c47c17893916ebe1b0fe76ccc4bc8e8a0c6e38fcf0f08afb", "url": "https://finance.yahoo.com/markets/stocks/articles/technotrans-se-wbo-ttr1-q2-010228002.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/technotrans-se-wbo-ttr1-q2-010228002.html", "title": "technotrans SE (WBO:TTR1) (Q2 2026) Earnings Call Highlights: Margin Resilience and Strategic ...", "content_text": "This article first appeared on GuruFocus. Revenue: EUR113.3 million in H1 2026, down 6% from EUR120.6 million in the prior year. EBIT: EUR8.0 million in H1 2026, compared to EUR8.4 million one year ago. EBIT Margin: Increased to 7.1% from 7.0% in the prior year. Gross Profit: EUR34.2 million, with gross margin improving to 30.2% from 29.8%. EBITDA: EUR11.2 million, compared to EUR11.9 million in the previous year; EBITDA margin rose to 9.9% from 9.8%. Net Profit: EUR4.9 million, down from EUR5.2 million in the prior year. Earnings Per Share: EUR0.71, compared to EUR0.75 in the previous year. F", "date_published": "2026-08-12T01:02:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "SCHO"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "SCHO", "name": "Aktieselskabet Schouw & Co.", "sentiment_url": "https://sharemaestro.com/sentiment/e767da2c-55a0-4f5a-871d-d98ce9e43e45/"}]}}, {"id": "source:075b73d293c7e70fcab278c37a05cfa686169b2d4b7e54589715f81be0413b7a", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "title": "Eli Lilly Scores Major Win in Weight-Loss Drug Race", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator. Lilly is one of the world's largest pharmaceutical companies, with diabetes and obesity treatments driving an increasing share of growth. Its portfolio includes injectable Mounjaro and Zepbound, while Foundayo, also known as orforglipron, extends its GLP-1 franchise into pills. Britain's Medicines and Healthcare products Regulatory Agency authorized Foundayo on Aug. 10 for weight management and Type 2 diabetes. The pill can be taken once daily at any time without food or water restrictions, potentially offering a convenience advantage for patients. The U.K. approval follows Foundayo's U.S. clearance on April 1. It also intensifies competition with Novo Nordisk, whose oral Wegovy received U.K. approval in June. Foundayo is still early in its commercial ramp, generating $98 million in second-quarter sales. But Lilly's broader obesity franchise is already powering extraordinary growth: companywide Q2 revenue jumped 48% to $23 billion, driven primarily by Mounjaro and Zepbound volume. Investor Takeaway The next question is how quickly Foundayo can translate regulatory approvals into meaningful sales. For investors, U.K. reimbursement will be critical. Although Foundayo is now approved, the MHRA says it is not currently available through the National Health Service, with NICE still needing to evaluate the treatment before broader NHS access. That makes reimbursement decisions, prescription growth and additional international approvals the key catalysts. If Foundayo gains traction alongside Zepbound rather than merely cannibalizing injections, Lilly could broaden the addressable GLP-1 population substantially. But slower uptake versus Novo Nordisk's competing pill, pricing pressure or limited reimbursement could temper the opportunity despite the regulatory momentum. View Comments", "date_published": "2026-08-11T19:07:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:e6b8fb8b7756e99aa4374c23943f6e0a9e8a1e41130e8092aada209c9a6372c1", "url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "content_text": "Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 \u2013 Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,702 shares at DKK 1,334.50, 2,069 shares at DKK 1,362.50, and 17,821 shares at DKK 1,615.00. Proceeds to the Company are approximately DKK 37.9 million. The increase corresponds to approximately 0.04% of the Company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly. Pursuant to section 32 of the Danish Capital Markets Act No. 464 of May 1, 2026, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 62,377,844 which is made up of 62,377,844 shares of a nominal value of DKK 1 each, corresponding to 62,377,844 votes. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X. Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This Company Announcement contains forward looking statements. The words \"believe,\" \"expect,\" \"anticipate,\" \"intend\" and \"plan\" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward ", "date_published": "2026-08-11T17:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "GMAB"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMAB", "name": "Genmab A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1a591078-2b4b-4c42-9ccb-8d5fba81165f/"}]}}]}